Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

Background: In the phase 3 DEFINE and CONFIRM trials, flushing and gastrointestinal (GI) events were associated with delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) treatment in people with relapsing-remitting multiple sclerosis (MS). To investigate these events, a post ho...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J MS Care
Autors principals: Phillips, J. Theodore, Selmaj, Krzysztof, Gold, Ralf, Fox, Robert J., Havrdova, Eva, Giovannoni, Gavin, Abourjaily, Heather, Pace, Amy, Novas, Mark, Hotermans, Christophe, Viglietta, Vissia, Meltzer, Leslie
Format: Artigo
Idioma:Inglês
Publicat: The Consortium of Multiple Sclerosis Centers 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599361/
https://ncbi.nlm.nih.gov/pubmed/26472945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-069
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars